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IntroductIon
Drug interaction is a very important clinical 
problem as well as recovery of diseases and a spe-
cific type of adverse effect, which is usually, may be 
predicted but cannot be prevented. Drug interaction 
is determined by biotransformation reactions through 
cytochrome P450s (CYP450s). There are 18 fami-
lies and 43 sub-families of CYP450s that have been 
identified by human. Almost all of drug used for drug 
therapy and administered through gastrointestinal 
pathway will be metabolized in gastrointestinal wall 
by phase I biotransformation (phase I metabolism). 
Drugs endured biotransformation process through 
CYP450 aid will be activated from previous prodrug 
form into an active form or will be metabolized into 
non-active form.1,2
Among the CYP450s families, the CYP1, CYP2 
and CYP3 are the most important parts in xenobiotics 
metabolism. They are highly expressed in the liver 
as well as extra-hepatic tissues including gastroin-
testinal tract, especially the small intestines.3 Drugs 
metabolized in the intestinal wall include cyclosporine, 
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AbstrAct
 Cytochromes P450 (CYP450) is a super-family of multigenes bound to heme and also a catalysator enzyme. 
Cytochrome P450s (1, 2, and 3) are the most important enzymes for biotransformation of drugs administered 
through gastrointestinal tract. The gastrointestinal tract is the first part of immune system against all of oral 
xenobiotics. Drug interaction may be predicted but it is hardly prevented. Thus, it frequently becomes clinical 
problem. 
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midazolam, NSAIDs, oral anticoagulant, H2-blocker, 
proton pump inhibitor.3,4 
This literature review is focused on the expression 
and distribution of CYP450 polymorphism (genetic 
variant) in gastrointestinal tract associated with its 
clinical significance. 
THE EFFECT OF CYP450 ENZYMES ON 
BIotrAnSforMAtIon of druG
CYP450 is a very strong microsomal absorbant 
band of 450 nm wavelength, which is resulted through 
dithionite treatment and additional CO gas (process 
of microsomal deletion). In addition, P indicates a 
pigment.
The strong binding of CO and ferrous heme will 
provide different absorbance spectrum for dithionite 
and CO. Such spectrum has been found since 1958.2
CYP450 is a main catalysator enzyme, which is 
important in drug biotransformation reaction. The 
genes of CYP450 family accommodate metabolism of 
chemical substance, toxic food and drugs.1 CYP450s 
are proteins bound to heme (membrane-bound 
heme-containing proteins), which respond to 
the metabolism of several endogenous components 
such as steroid, fatty acids, as well as other drugs and 
xenobiotics.3 CYP450s have important role in phase 
I biotransformation, which occurs in endoplasmic 
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reticulum as well as in the conjugated cytosolic 
fraction.5 Figure 1 shows the schematic mechanisms 
of oxygen activation and drugs oxidation through 
multiple steps which indicate that xenobiotics sub-
strate react with the oxidized Fe3+ of CYP450 to form 
an enzyme. 
CYP450 accepts electrons of NADPH, which 
reduce the oxidation complex of CYP450 and xe-
nobiotics (Fe2+). The last step includes an oxygen 
atom (H2O) released and the other oxygen atom 
is transferred into substrate (figure 1). The most 
dominant CYP450s enzymes in biotransformation of 
drugs are CYP1, CYP2 and CYP3 (the proportion is 
of drug is genetic polymorphism of CYP450 enzyme.1 
Mutation of CYP450 gene or enzyme deficiency is 
obviously associated with some disease and induces 
some CYP450s, which have pro-carcinogenic risk 
and it also has important role in providing accurate 
therapy.4,5,6
Almost one per third of CYP450s genes is 
CYP2 and most of its proteins are able to perform 
hydroxylation reaction against steroid and the other may 
provide protection against toxins that enter into the body 
together with food intake.2 The CYP450 chromo-
some can be well-detected, either by non-invasive or 
invasive method. The non-invasive markers may be 
detected through urine and blood specimens as well 
as the air of breath; while invasive method needs 
specimen biopsies.2,3,7,8
DISTRIBUTION OF CYP450S IN THE MUCOSA OF 
GAStroIntEStInAl trAct
Food, drugs or other xenobiotics entered into 
gastrointestinal tract will experience biotransformation 
process (phase I metabolism) on the intestinal wall 
and almost all of xenobiotic components may activate 
enzymes into toxic or carcinogenic form.7 
The presence of drugs in gastrointestinal tract is 
corresponding to its presence in blood. This fact is 
obvious in the liver donor who had received oral 
cyclosporine therapy and revealed a detected cy-
closporine blood level in the portal vein, when 
the drug had reached intestines. Similar fact is also 
found for midazolam.3 
The evidence should be proven by thorough 
examination of gastrointestinal mucosa, i.e. specimen 
biopsies. Gastric, duodenal and colon biopsies can 
be easily performed by routine endoscopic examina-
tion. Specimen biopsies are put in the liquid nitrogen 
and kept in temperature of -70oC. Subsequently, it is 
prepared for mRNA examination and followed 
by CDNA synthesis as well as real-time PCR. 
The expression and polymorphism of CYP450 en-
zymes of each specimen biopsy can be analyzed.3,7,8
Thorn et al, provided evidence about mRNA 
expressions of CYP2E1, CYP3A4, and CYP2A5 
present in all of gastrointestinal mucosa (stomach, 
duodenum, right and left colon, rectum). The most 
frequent mRNA expression of CYP2E1 present in 
stomach and duodenum, while mRNA of CYP3A4 
present in duodenum and mRNA of CYP3A5 pres-
ent in duodenum and stomach.3 Von Richter et al, 
compared p-glycoprotein mRNA expression of 
CYP3A4 in enterocytes of duodenum or proximal 
jejunum as well as in the hepatocytes.
It is evident that mRNA expression of CYP3A4 
in the enterocytes is 3 times higher and p-glyco-
protein expression is 7 times higher compared to 
depicted in figure 2).1
Increased CYP450 synthesis is correlated to 
the exposures of drugs and pollutants, which are 
followed further by increased biotransformation rate 
and usually also correlated to increased toxicity. 
In addition, inhibited drug biotransformation will cause 
increased drug concentration, prolonged pharmacolog-
ic response and increased risk of drug-induced toxicity. 
In fact, the most important factor in biotransformation 
Figure 1. Mechanisms of CYP450s in oxygen activation and drug 
oxidation.1
Figure 2. Proportion of drug metabolisms by the most dominant 
CYP450.1
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the expressions in the hepatocytes.8 This study 
indicated that the expressions of CYP2E1, CYP3A4, 
CYP2A5 and p-glycoprotein worked together in 
a synergy as bioavailability barrier or oral drugs. 
P-glycoprotein is a protein transporter bound to 
mucosa membrane of gastrointestinal tract, liver 
and kidney and it is coded by multi-drug resistance 
genes. Increased expressions of CYP enzymes are 
associated with increased incidence rate of multi-
drugs resistance, which are proven by increased 
p-glycoprotein expression. In fact, the p-glycoprotein 
(p-gp) expression increases in all along the gastro- 
intestinal tract, from stomach to the descending colon 
and slightly reduced at the rectum.3
Bergheim et al indicated the distribution of 
CYP2C, CYP2E1, CYP3A4, and CYP3A5 in colon 
mucosa. CYP2C expression was more frequent in 
the ascending colon compared to the descending colon 
and sigmoid. CYP2E1 expression was not detected in 
the ascending colon. CYP3A4 expression was simi-
lar in all colon and CYP3A5 was more frequent in 
the descending colon (2 times greater) and the sig-
moid (three times greater) compared to the ascending 
colon.7 
Figures below are illustrations of mRNAs of 
CYPs in gastrointestinal mucosa of specimen biopsies 
analyzed by electrophoresis and immunoblotting 
(figure 3 and 4) and illustration of mRNA relative 
concentration (figure 5 and 6). 
CORRELATION BETWEEN CYP450 POLYMOR-
PHISM And GAStroIntEStInAl dISEASE
The CYP2 family is the most abundant type found 
in human being, which is 1/3 part of CYP450s en-
zymes. It has multiple polymorphism capacity that 
may reduce or increase enzyme activity, which clini-
cally can be categorized as poor metabolizers, exten-
sive metabolizers and ultra-rapid metabolizers.5 CYP 
isoenzyme is controlled by genetic factors. It has 
different expression among individuals and is affected 
by multiple factors such as tobacco smoking, etha-
nol consumption, environment, disease and genetic 
factors.5,9
Kawamura et al, reported the effect of proton 
pump inhibitor (PPI), lansoprazole, in inhibiting 
gastric acid secretion, which is affected by CYP2C19 
polymorphism. In homozygous extensive metaboliz-
ers (no mutation occur in exon 4 and 5), the effect of 
gastric acid suppression by PPI is not effective 
because there is rapid metabolism caused by high 
enzyme activity of CYP2C19. On the contrary, in poor 
metabolizers (mutation in both CYP2C19 alleles) 
effectively inhibit the increased gastric acid secre-
Figure 4. (A) Western blots images of CYP3A4 and CYP3A5 (right 
lane – hepatocytes, left lane – enterocytes). (B) Western blots of 
p-glycoprotein from hepatocytes and enterocytes biopsies. 
Protein load of 5 ug for CYP3A4; 50 ģg for CYP3A5; 40 ģg for he-
patocytes P-gp and 20 ģg for enterocytes P-gp.8
Figure 3. (A) Integrity of colon mucosa biopsy with gel agarose 
mRNA (lane 1 and 10 positive controls); (B) Photomicrograph 
image of RT-PCR (lane 1 = Histone 3.3; lane 2 = CYP3A5; lane 3 = 
CYP2E1; lane 4 = CYP3A4; lane 5 = CYP2C; bp= base pairs)7
Figure 5. The percentage of gastrointestinal mucosa biopsies with 
mRNA expressions over detection limit (c.o. > 38).5 
Figure 6. Quantitative analyses on mRNA expressions of CYP2C, 
CYP2E1, CYP3A4, and CYP3A5 in biopsies of colon mucosa 
 (p < 0.05 compared to ascending colon).7
Volume 8, Number 3, December 2007 83
The Clinical Significance of CYP450 in Gastrointestinal Tract
tion. 
In heterozygous extensive metabolizers (muta-
tion in an allele), the efficacy of PPI is intermediate. 
The expression of CYP2C19 polymorphism affects 
PPI therapeutic responses such as erosive reflux 
esophagitis therapy and maintenance therapy of reflux 
esophagitis. There is higher recurrence rate of erosive 
reflux esophagitis in extensive metabolizers (EM) 
compared to the poor metabolizers (PM). Consequent-
ly, small dose of long-term lansoprazole therapy is not 
efficient for erosive remission in homozygous and 
heterozygous extensive metabolizers genotypes. 
In contrast, poor-metabolizers genotype needs small 
dose of lansoprazole to maintain erosive remission.10
Sapone et al, reported the effect of CYP2C19 
(*2 and *3) and CYP3A4 (*1B, *2, and *3), either 
homozygous or heterozygous extensive metabolizers 
(homoEM or heteroEM), in eradicating H. pylori. 
It is predicted that the failure of H. pylori 
eradication tends to be higher in the homoEM than 
the heteroEM. In CYP3A4*1B, the eradication has 
not been reached. In addition, a positive synergy 
of CYP3A4 and CYP2C19 heteroEM has affected 
the eradication of H. pylori.11 High CYP3A4 
expression in enterocytes (intestines) may be induced 
by single oral dose of omeprazole theapy.8 Mutation of 
CYP2C19 genotype and its effect on PPI metabolism 
may influence the H. pylori eradication therapy us-
ing two or three antibiotics (dual or triple therapy).12 
The high CYP2C19 expression is associated with pep-
tic ulcer.2 In addition, gastritis complication, peptic ul-
cer and NSAIDs-induced gastrointestinal bleeding are 
increasing in CYP2C9 polymorphism.4
The high level of CYP450 is correlated to increased 
risk of cancer incidence, good therapeutic response 
and drug resistance. CYP1A2 polymorphism is 
correlated to increased risk of colon cancer when it is 
activated by carcinogenic components such as tobacco 
smoking.2 The absent CYP2E1 expressions in colon 
may become important factor because it may suggest 
that the organ tends to turn into cancer.7 CYP2E1 
enzyme is strongly correlated to the incidence of 
gastric cancer, and naturally the enzyme activity is 
 induced by alcohol, tobacco smoking and other 
endogenous gastric factors. Nishimoto et al, studied 
about CYP2E1 polymorphism on gastric cancer and 
found that the CYP2E1 genotype variant is corre-
lated to reduced cancer risk of upper gastrointestinal 
tract. However, the correlation between CYP2E1 
polymorphism and gastrointestinal cancer is still 
controversial up to now.6
concluSIon
Gastrointestinal mucosa is the first location where 
oral xenobiotics undergo biotransformation process 
through the aid of CYP450 enzymes. Subfamily 1, 
2, and 3 of CYP450 are the most important enzyme 
in oral drug metabolism. Polymorphism of CYP450 
enzymes in gastrointestinal mucosa affects 
the biotransformation activity of oral drugs (poor 
metabolizers, extensive metabolizers or ultra rapid 
metabolizers). The clinical consequences will affect 
good therapeutic response. Therefore, we should be 
careful in determining the effective (individual) dose 
as well as avoiding multiple drugs therapy in order 
to reduce the drug effect and oral multidrugs resis-
tance. Polymorphism of CYP450 enzyme induced by 
a lcohol ,  tobacco  smoking  or  endogenous 
gastro-intestinal factor will activate carcinogenic 
factors in the gastrointestinal tract. 
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